An evaluation of Oregon's evidence-based practitioner-managed prescription drug plan

Health Affairs

Volumn 25, Issue 5, 2006, Pages 1423-1432

  Hartung, Daniel M ^a   Ketchum, Kathy L ^b   Haxby, Dean G ^c  

^a OREGON STATE UNIVERSITY   (United States)

^b Medicaid related programs ^*

^c Drug Use Research and Management Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; INSURANCE; MANAGEMENT; STANDARD; UNITED STATES; UTILIZATION REVIEW;

EVIDENCE-BASED MEDICINE; HEALTH PLAN IMPLEMENTATION; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; OREGON; PRACTICE MANAGEMENT, MEDICAL; STATE HEALTH PLANS; UNITED STATES;

EID: 33749350825     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.5.1423     Document Type: Article

References (17)

1. J. Crowley, D. Ashner, and L. Elam, Medicaid Outpatient Prescription Drug Benefits: Findings from a National Survey, December 2003, http://www.kff.org/ medicaid/4164.cfm (accessed 30 May 2006);
2. M.M. Mello, D.M. Studdert, and T.A. Brennan, "The Pharmaceutical Industry versus Medicaid - Limits on State Initiatives to Control Prescription-Drug Costs," New England Journal of Medicine 350, no. 6 (2004): 608-613;
3. and J.K. Iglehart, "The Dilemma of Medicaid," New England Journal of Medicine 348, no. 21 (2003): 2140-2148.
4. Oregon Legislative Assembly Senate Bill 819, 71st Oregon Legislative Assembly, 2001 Regular Session.
5. Drug Effectiveness Review Project, "Quality Assessment Methods for Drug Class Reviews for the Drug Effectiveness Review Project," http://www.ohsu.edu/drugeffectiveness/methods/QualityAssessmentDERP.pdf (accessed 13 February 2006).
6. A.M. Garber, "Evidence-based Coverage Policy," Health Affairs 20, no. 5 (2001): 62-82.
7. C. Bernasek et al., Oregon's Medicaid PDL: Will an Evidence-based Formulary with Voluntary Compliance Set a Precedent for Medicaid? January 2004, http://www.kff.org/medicaid/4173.cfm (accessed 18 April 2006).
8. Oregon's Practitioner-Managed Drug Plan, "Evidence-based Medicine Reports," http://www.oregon.gov/DAS/OHPPR/ORRX/HRC/evidence_based_reports. shtml (accessed 18 April 2006).
9. Oregon Legislative Assembly House Bill 3624, 72d Oregon Legislative Assembly, 2003 Regular Session.
10. J.E. Rossouw et al., "Risks and Benefits of Estrogen plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women's Health Initiative Randomized Controlled Trial," Journal of the American Medical Association 288, no. 3 (2002): 321-333;
11. and D. Grady et al., "Cardiovascular Disease Outcomes during 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)," Journal of the American Medical Association 228, no. 1 (2002): 49-57.
12. A.K. Wagner et al., "Segmented Regression Analysis of Interrupted Time Series Studies in Medication Use Research," Journal of Clinical Pharmacy and Therapeutics 27, no. 4 (2002): 299-309. Details about the modeling process are described in an online appendix, available at http://content. healthaffairs.org/cgi/content/full/25/5/1423/DC1.
13. C. Mann and S. Artiga, "The Impact of Recent Changes in Health Care Coverage for Low-Income People: A First Look at the Research following Change in Oregon's Medicaid Program," Issue Paper, June 2004, http://www.kff.org/ medicaid/7100a.cfm (accessed 13 February 2006).
14. Crowley et al., Medicaid Outpatient Prescription Drug Benefits.
15. S.B. Soumerai, "Benefits and Risks of Increasing Restrictions on Access to Costly Drugs in Medicaid," Health Affairs 23, no. 1 (2004) 135-146.
16. J.D. Kleinke, "Evidence-based Medicine: Health Care's Next Holy War," Journal of Managed Care Pharmacy 11, no. 4 Supp. (2005): S3-S6;
17. and R. Padrez et al., The Use of Oregon's Evidence-based Reviews for Medicaid Pharmacy Policies: Experiences in Four States, May 2005, http://www.kff.org/medicaid/7319.cfm (accessed 18 April 2006).